AGL 38.51 Increased By ▲ 0.94 (2.5%)
AIRLINK 129.25 Decreased By ▼ -3.25 (-2.45%)
BOP 5.63 Decreased By ▼ -0.01 (-0.18%)
CNERGY 3.83 Increased By ▲ 0.06 (1.59%)
DCL 8.70 Decreased By ▼ -0.17 (-1.92%)
DFML 41.95 Increased By ▲ 0.95 (2.32%)
DGKC 88.50 Decreased By ▼ -1.66 (-1.84%)
FCCL 34.89 Decreased By ▼ -0.19 (-0.54%)
FFBL 66.79 Increased By ▲ 0.29 (0.44%)
FFL 10.52 Increased By ▲ 0.37 (3.65%)
HUBC 108.60 Increased By ▲ 2.20 (2.07%)
HUMNL 14.66 Increased By ▲ 1.26 (9.4%)
KEL 4.77 Decreased By ▼ -0.09 (-1.85%)
KOSM 6.98 Increased By ▲ 0.13 (1.9%)
MLCF 41.72 Decreased By ▼ -0.08 (-0.19%)
NBP 59.65 Increased By ▲ 1.07 (1.83%)
OGDC 183.65 Increased By ▲ 2.40 (1.32%)
PAEL 26.12 Increased By ▲ 0.42 (1.63%)
PIBTL 5.95 Increased By ▲ 0.12 (2.06%)
PPL 147.75 Decreased By ▼ -0.65 (-0.44%)
PRL 23.57 Increased By ▲ 0.35 (1.51%)
PTC 16.56 Increased By ▲ 1.32 (8.66%)
SEARL 68.29 Decreased By ▼ -0.50 (-0.73%)
TELE 7.17 Decreased By ▼ -0.07 (-0.97%)
TOMCL 35.80 Decreased By ▼ -0.20 (-0.56%)
TPLP 7.74 Increased By ▲ 0.34 (4.59%)
TREET 14.20 Decreased By ▼ -0.04 (-0.28%)
TRG 50.41 Decreased By ▼ -0.44 (-0.87%)
UNITY 26.75 Increased By ▲ 0.35 (1.33%)
WTL 1.22 Increased By ▲ 0.01 (0.83%)
BR100 9,809 Increased By 41.1 (0.42%)
BR30 29,711 Increased By 311.1 (1.06%)
KSE100 92,381 Increased By 443.3 (0.48%)
KSE30 28,851 Increased By 107.7 (0.37%)
World

J&J to deliver up to 400 million Covid vaccines to Africa

  • AVAT can order an additional 180 million doses, for a combined total of up to 400 million doses through 2022.
Published March 29, 2021

WASHINGTON: Up to 400 million doses of Johnson & Johnson's Covid-19 vaccine will be made available to African countries, the US pharmaceutical giant said Monday.

The availability of the single-shot vaccine will be subject to national regulatory approvals in the African Union's 55 member states, with the first shipments expected to arrive in the third quarter of 2021.

"No one is safe until everyone is safe, and we have been committed to equitable, global access to new Covid-19 vaccines," J&J's CEO Alex Gorsky said in a statement.

The company said Janssen Pharmaceutica, a J&J subsidiary, had entered into an agreement with the African Vaccine Acquisition Trust (AVAT) to initially make available up to 220 million doses of its vaccine.

AVAT can order an additional 180 million doses, for a combined total of up to 400 million doses through 2022.

J&J says its vaccine candidate protects against Covid-19 in broad geographical regions -- including those with new variants of the disease.

In a global trial of almost 40,000 people, the J&J vaccine's efficacy against severe disease was 85.4 percent, but it fell to 66.1 percent when including moderate forms of the disease.

But the vaccine has won praise for its single dosage and because it does not need to be frozen -- unlike the shots from Moderna and Pfizer -- making distribution much simpler.

Comments

Comments are closed.